So first off, I'm Michael Maglin. I'm the CEO of CraniUS, and I'm here today to talk to you about neuro pass. And neuro pass is the first skull embedded drug delivery platform that is going to overcome the challenge of the blood brain barrier and give long term and direct access to the brain tissue. So the problem is staggering, and I don't think I need to tell anybody in this room. I this room. I feel like anybody in this room has had somebody in their life impacted by a neurological disorder. One in three globally suffer or have suffered from one of these devastating diseases. And the bigger challenge is, if you think about all the organs in the body, the one that has seen the least amount of innovation over the last 50 years is the brain. It is very much still a mystery, and we are here to overcome that challenge. The reason for that is something called the blood brain barrier, and essentially, to think about it in layman's terms, it is an extra layer of protection that our bodies have built up over 1000s of years of evolution to protect our brain from harmful substances and chemicals, which is a good thing. However, on the downside, when you think about any type of therapeutic taken by pill form or through an injection into the bloodstream, through the system, less than 2% of that medicine is actually getting to the brain tissue, because the blood brain barrier sees this as a harmful substance. So now you can understand why we've seen such little progress against brain disease when less than 2% of the medicine is actually getting to where it needs to be. The answer really has been, unfortunately, over the last 50 years for the pharmaceutical industry, has been to increase dosages of current drugs in hopes of really take a Mack truck approach to the blood brain barrier. And the challenge with that is we're seeing it still being ineffective, and there's a lot of collateral damage that has happened to other organs in the body. So they say a picture tells 1000 words. I'm going to give you guys a quick two minute video to demonstrate the technology of neuropaths. Traditional methods of medicine delivery to the brain have been significantly hindered by the blood brain barrier, blocking up to 98% of large molecules needed for current therapies. Physicians cannot simply increase the dose, as this approach creates collateral damage and other systems within the body. To address this unmet clinical need, cranius Therapeutics is developing. Neuro pass the world's first and only fully implantable skull embedded drug delivery system designed to bypass the blood brain barrier, transporting medicine directly to the brain tissue. The neuro pass system utilizes a dual catheter, micro fluidics platform to deliver both localized and bilateral disease treatments, minimizing systemic toxicity, delivering drugs to the right place with a precise flow rate. It is a drug and disease agnostic platform enabling treatment of multiple brain diseases, including malignant brain tumors, Alzheimer's, Parkinson's and medicine resistant epilepsy. Its discrete implant design is concealed beneath the skin with an easily refillable port that uses a syringe or refill device for long term or sustained access and delivery, thereby supporting customizable treatment regimens over time, enabling adjustments as the patient's disease state evolves. The neuro pass is MRI Lucent, providing minimal artifact and no visual impact to the scan, allowing physicians to clearly track the disease state over time, join us in helping transform the way brain disease is treated with the opportunity to impact millions of patients. So as you can see, it's quite an undertaking, and we're very proud of the work the team has done, but it's really been the culmination of a journey of almost 15 years by our founder, Dr Chad Gordon, who is a full professor at Johns Hopkins University and the head of neuro plastic surgery and reconstructive surgery. Dr Gordon is actually classically trained as a plastic surgeon. Did his residency at the Cleveland Clinic and then went on to Mass General for his fellowship. It wasn't until he got to Johns Hopkins, though that he started working with some of the best neurosurgeons in the world. And while the neurosurgeons are great at treating the engine of the car or the brain and disease itself, they don't think a lot about the reconstructive angle and the scalp and scalp, the skull and scalp. And so this is where Dr Gordon saw a blue ocean of opportunity traditional cranial implants that have been around for decades really account for bone loss that you see in surgery. What it didn't account for, though, is in over 50% of patients three to six months after having a brain surgery, they have basically muscle and fat degradation in the side of their head, if you feel that soft area that is not accounted for by the cranial implant. And so patients were walking in with skull defects, and Dr Gordon has become the world leading expert in fixing those defects. His first invention, which he licensed to Stryker on a 20 year deal, was that bulk out of that area to account for not just the bone, but also the muscle and fat. The reason that was important outside of the deal is the bone is only four to five millimeters thick, so patient. Super thin, but this area that he carved out was an inch and a half to two inches thick. And what he realized for the long term is he now had a place where he actually could implant technology within the cranial implant itself. And so instead of rushing to medicine delivery, which is going to be the holy grail to overcome the blood brain barrier, he spent the next five years conducting three first in human surgeries at Johns Hopkins. And if you think about that, many surgeons don't do one of those in their career. He did three in five years. And he took existing technology out in the market with his first one for epilepsy, second with a hydrocephalus shunt. These are products that have been very clunky and hard with placement causing chronic pain, infection poking up through the skin. And instead, he embedded this within the cranial implant space, and these patients were able to see great outcomes. The third first in human surgery he conducted was the first smart cranial implant, and it was a woman who had a gunshot was a gunshot victim and had pressure build up in her head. And he actually put the world's first biosensor into the cranial implant to make sure he could measure the intracranial pressure and be able to track the patient, and this led to the formation of cranius and where we're at today. So in the last couple years, we've done a lot of great things with the first $20 million that we raised at the company, obviously building this technology. But I look at it as the last 15 years have truly been risk mitigation, leading up to our very successful swine study and pre clinical work in 2023 we've already had some deep conversations with strategics in both the drug and the device side, and we'll be continuing those in earnest over the next couple months and years. We have a robust portfolio. Everything we have is a platform, including the device itself, which is gonna be able to treat multiple brain diseases, and so that platform creates a lot of value for our shareholders. We have 11 issued today, with three that are in process. We have the opportunity to monetize in the next 24 to 36 months, and then our team of over 35 globally working on this product has collectively worked on every implantable pump and drug delivery system that has come out in the last 25 years. So the market opportunity, just for our initial indications, is $9 billion glioblastoma, glioblastoma, or malignant brain tumors, being the lowest hanging fruit, because 90% of these patients are already having surgery. So placing this implant in that can deliver medicine is a huge advantage for them. But Parkinson's and Alzheimer's are going to be fast followers there. The path to revenue is really two fold. We have the opportunity to disrupt the cranial implant world that has been around with me to products for 50 Years and actually have a functional cranial implant. That opportunity is $100 million plus annually. We also have a several drug companies that are interested in working with us, that have drugs they know that can work for these diseases, but they can't get through directly to the brain tissue, and need the neuro pass device. And then, obviously, this opens up the world for new routes of administration, for drugs to be approved for direct administration to the brain. Looking out for the next couple years, we have frozen our design. We're working towards a first in human study, and then moving to a class two de novo submission in early part of 2027 with the goal to have commercialization by the end of 2027 early 28 I'm only mentioning three of the folks that are working on our executive team, but as I mentioned, we have 35 folks around the world working with some of the world's leading design firms in Switzerland, working with some of the best manufacturing teams in Boston, And I can give you more detail later on. And what we're looking is this is our second fundraise. The first was $20 million we're now looking for $20 million to fund us through that de novo submission and getting us to commercialization. We've already raised 11 of that $20 million so we're looking for additional investors to close the round in the next 45 to 60 days. And again, we have the opportunity to monetize and or exit we believe in the next two to three years. Thank you very much.